$DXCM
DEXCOM INC

2020 Q1 Form 10-Q Financial Statement

#000109355720000141 Filed on April 28, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $405.1M $280.5M
YoY Change 44.42% 52.11%
Cost Of Revenue $148.6M $111.7M
YoY Change 33.03% 70.53%
Gross Profit $256.5M $168.8M
YoY Change 51.95% 41.97%
Gross Profit Margin 63.32% 60.18%
Selling, General & Admin $149.8M $124.2M
YoY Change 20.61% 18.51%
% of Gross Profit 58.4% 73.58%
Research & Development $73.10M $59.00M
YoY Change 23.9% 31.7%
% of Gross Profit 28.5% 34.95%
Depreciation & Amortization $13.00M $9.900M
YoY Change 31.31% 65.0%
% of Gross Profit 5.07% 5.86%
Operating Expenses $222.9M $183.2M
YoY Change 21.67% 22.46%
Operating Profit $33.60M -$14.40M
YoY Change -333.33% -53.09%
Interest Expense $15.40M $14.90M
YoY Change 3.36% 210.42%
% of Operating Profit 45.83%
Other Income/Expense, Net $4.200M $6.900M
YoY Change -39.13% 165.38%
Pretax Income $22.40M -$26.60M
YoY Change -184.21% 10.83%
Income Tax $2.500M $300.0K
% Of Pretax Income 11.16%
Net Earnings $19.90M -$26.90M
YoY Change -173.98% 11.16%
Net Earnings / Revenue 4.91% -9.59%
Basic Earnings Per Share $0.22 -$0.30
Diluted Earnings Per Share $0.21 -$0.30
COMMON SHARES
Basic Shares Outstanding 91.80M shares 90.30M shares
Diluted Shares Outstanding 94.10M shares 90.30M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.511B $1.358B
YoY Change 11.23% 160.4%
Cash & Equivalents $584.6M $1.285B
Short-Term Investments $925.9M $72.90M
Other Short-Term Assets $42.60M $27.00M
YoY Change 57.78% 35.68%
Inventory $141.9M $101.1M
Prepaid Expenses
Receivables $300.7M $204.7M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.996B $1.691B
YoY Change 18.03% 131.84%
LONG-TERM ASSETS
Property, Plant & Equipment $346.1M $221.4M
YoY Change 56.32% 45.28%
Goodwill $18.60M $18.60M
YoY Change 0.0% 51.22%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.70M $15.50M
YoY Change -11.61% 453.57%
Total Long-Term Assets $452.2M $283.2M
YoY Change 59.68% 69.07%
TOTAL ASSETS
Total Short-Term Assets $1.996B $1.691B
Total Long-Term Assets $452.2M $283.2M
Total Assets $2.448B $1.974B
YoY Change 24.01% 120.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $110.2M $90.30M
YoY Change 22.04% 132.13%
Accrued Expenses $230.8M $140.8M
YoY Change 63.92% 69.03%
Deferred Revenue $1.800M $2.700M
YoY Change -33.33%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $500.0K
YoY Change
Total Short-Term Liabilities $342.8M $235.4M
YoY Change 45.62% 88.17%
LONG-TERM LIABILITIES
Long-Term Debt $1.087B $1.038B
YoY Change 4.72% 206.35%
Other Long-Term Liabilities $20.90M $18.10M
YoY Change 15.47% -3.21%
Total Long-Term Liabilities $20.90M $18.10M
YoY Change 15.47% -3.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $342.8M $235.4M
Total Long-Term Liabilities $20.90M $18.10M
Total Liabilities $1.513B $1.305B
YoY Change 15.93% 174.76%
SHAREHOLDERS EQUITY
Retained Earnings -$675.8M -$823.7M
YoY Change -17.96% 18.35%
Common Stock $1.707B $1.591B
YoY Change 7.29% 41.7%
Preferred Stock
YoY Change
Treasury Stock (at cost) $100.0M $100.0M
YoY Change 0.0%
Treasury Stock Shares 800.0K shares 800.0K shares
Shareholders Equity $934.5M $668.6M
YoY Change
Total Liabilities & Shareholders Equity $2.448B $1.974B
YoY Change 24.01% 120.12%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income $19.90M -$26.90M
YoY Change -173.98% 11.16%
Depreciation, Depletion And Amortization $13.00M $9.900M
YoY Change 31.31% 65.0%
Cash From Operating Activities $1.900M $11.80M
YoY Change -83.9% -235.63%
INVESTING ACTIVITIES
Capital Expenditures $33.20M $39.30M
YoY Change -15.52% 156.86%
Acquisitions
YoY Change
Other Investing Activities $400.0K $0.00
YoY Change -100.0%
Cash From Investing Activities $130.6M $131.3M
YoY Change -0.53% -952.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.700M $5.000M
YoY Change 34.0% 19.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.500M $4.900M
YoY Change 32.65% 16.67%
NET CHANGE
Cash From Operating Activities $1.900M $11.80M
Cash From Investing Activities $130.6M $131.3M
Cash From Financing Activities $6.500M $4.900M
Net Change In Cash $138.5M $148.6M
YoY Change -6.8% -814.42%
FREE CASH FLOW
Cash From Operating Activities $1.900M $11.80M
Capital Expenditures $33.20M $39.30M
Free Cash Flow -$31.30M -$27.50M
YoY Change 13.82% 14.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001093557
CY2019Q1 dxcm Fair Value Assets Level3 Transfers Amount
FairValueAssetsLevel3TransfersAmount
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92400000 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93100000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91600000 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92300000 shares
CY2019Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P12M
CY2019Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2019Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2020Q1 us-gaap Litigation Reserve
LitigationReserve
0 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
800000 shares
CY2020Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
800000 shares
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
000-51222
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
DEXCOM, INC.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0857544
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6340 Sequence Drive
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2020Q1 dei City Area Code
CityAreaCode
858
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
200-0200
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value Per Share
CY2020Q1 dei Trading Symbol
TradingSymbol
DXCM
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
92344878 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584600000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
446200000 USD
CY2020Q1 dxcm Debt Securities Available For Sale And Equity Securities
DebtSecuritiesAvailableForSaleAndEquitySecurities
925900000 USD
CY2019Q4 dxcm Debt Securities Available For Sale And Equity Securities
DebtSecuritiesAvailableForSaleAndEquitySecurities
1087100000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
300700000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
286300000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
141900000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
119800000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
42600000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30000000.0 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
1995700000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1969400000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
346100000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321300000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
73800000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71500000 USD
CY2020Q1 us-gaap Goodwill
Goodwill
18600000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
18600000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13700000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14200000 USD
CY2020Q1 us-gaap Assets
Assets
2447900000 USD
CY2019Q4 us-gaap Assets
Assets
2395000000.0 USD
CY2020Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
267500000 USD
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
256400000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
59000000.0 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
88500000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14500000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13600000 USD
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1800000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1700000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
342800000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
360200000 USD
CY2020Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1072400000 USD
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1059700000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
77300000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
72400000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20900000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20100000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
1513400000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
1512400000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
100000 USD
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
100000 USD
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1706500000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1675900000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3700000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2300000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-675800000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-695700000 USD
CY2020Q1 us-gaap Treasury Stock Value
TreasuryStockValue
100000000.0 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
100000000.0 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
934500000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
882600000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2447900000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2395000000.0 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405100000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
280500000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
148600000 USD
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
111700000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
256500000 USD
CY2019Q1 us-gaap Gross Profit
GrossProfit
168800000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73100000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59000000.0 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149800000 USD
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
124200000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
222900000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
183200000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
33600000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14400000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
15400000 USD
CY2019Q1 us-gaap Interest Expense
InterestExpense
14900000 USD
CY2020Q1 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
0 USD
CY2019Q1 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
-4200000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4200000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6900000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
22400000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26600000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2500000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
19900000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-26900000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91800000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90300000 shares
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94100000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90300000 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
19900000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-26900000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-700000 USD
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2100000 USD
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
100000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1400000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
100000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21300000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26800000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
882600000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
300000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6400000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23900000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
19900000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1400000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
934500000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
663300000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
200000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4800000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25000000.0 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-26900000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
100000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
668600000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
19900000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-26900000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000000.0 USD
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9900000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
23900000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
25000000.0 USD
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12700000 USD
CY2019Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12200000 USD
CY2020Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0 USD
CY2019Q1 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-4200000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-100000 USD
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-300000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14700000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-21500000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
22200000 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
30400000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7600000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5200000 USD
CY2020Q1 dxcm Increase Decreasein Operating Lease Assetsand Liabilities Net
IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet
400000 USD
CY2019Q1 dxcm Increase Decreasein Operating Lease Assetsand Liabilities Net
IncreaseDecreaseinOperatingLeaseAssetsandLiabilitiesNet
200000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5300000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
25500000 USD
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-29100000 USD
CY2019Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-21100000 USD
CY2020Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
1000000.0 USD
CY2019Q1 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-3000000.0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1900000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11800000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
365800000 USD
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
50700000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
530000000.0 USD
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
222500000 USD
CY2020Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 USD
CY2019Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
1200000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33200000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39300000 USD
CY2020Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
400000 USD
CY2019Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130600000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
131300000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6700000 USD
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000.0 USD
CY2020Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-200000 USD
CY2019Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-100000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6500000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4900000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-500000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
600000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
138500000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
148600000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
446400000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1137100000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
584900000 USD
CY2020Q1 us-gaap Restricted Cash
RestrictedCash
300000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1285700000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584600000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1285100000 USD
CY2019Q1 us-gaap Restricted Cash
RestrictedCash
600000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
584900000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1285700000 USD
CY2020Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
19600000 USD
CY2019Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
10100000 USD
CY2020Q1 dxcm Right Of Use Asset Obtained In Exchange For Lease Liabilities
RightOfUseAssetObtainedInExchangeForLeaseLiabilities
5300000 USD
CY2019Q1 dxcm Right Of Use Asset Obtained In Exchange For Lease Liabilities
RightOfUseAssetObtainedInExchangeForLeaseLiabilities
45200000 USD
CY2020Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px dotted #58a618;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#58a618;font-style:italic;font-weight:bold;">Organization and Business</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">DexCom, Inc.</span><span style="font-family:inherit;font-size:10pt;"> is a medical device company focused on the design, development and commercialization of</span><span style="font-family:inherit;font-size:10pt;"> continuous glucose monitoring, or CGM systems</span><span style="font-family:inherit;font-size:10pt;"> for use by people with diabetes and by healthcare providers. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to </span><span style="font-family:inherit;font-size:10pt;">DexCom, Inc.</span><span style="font-family:inherit;font-size:10pt;"> and its subsidiaries.</span>
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px dotted #58a618;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#58a618;font-style:italic;font-weight:bold;">Use of Estimates</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </span><span style="font-family:inherit;font-size:10pt;">GAAP</span><span style="font-family:inherit;font-size:10pt;"> requires us to make certain estimates and assumptions that affect the amounts reported in our financial statements and the disclosures made in the accompanying notes. Areas requiring significant estimates include transaction price, net accounts receivable, excess or obsolete inventories and the valuation of inventory, and accruals for litigation contingencies. Despite our intention to establish accurate estimates and use reasonable assumptions, actual results may differ from our estimates. </span>
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/><td style="width:20%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px dotted #58a618;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#58a618;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div></td></tr></table></div></div>Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term marketable securities, and accounts receivable. We limit our exposure to credit risk by placing our cash and investments with high credit quality financial institutions. We have also established guidelines regarding diversification of our investments and their maturities that are designed to maintain principal and maximize liquidity. We review these guidelines periodically and modify them to take advantage of trends in yields and interest rates and changes in our operations and financial position.
CY2020Q1 dxcm Revenue Recognition Sales Returns Coverage Period
RevenueRecognitionSalesReturnsCoveragePeriod
P30D
CY2020Q1 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
6900000 USD
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1100000 USD
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2400000 USD
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3600000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2100000 USD
CY2020Q1 dxcm Amortization Period For Incentive Compensation Costs
AmortizationPeriodForIncentiveCompensationCosts
P1Y
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
19900000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-26900000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91800000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90300000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94100000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90300000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13400000 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16700000 shares
CY2020Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
463700000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
925900000 USD
CY2020Q1 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
1800000 USD
CY2020Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1391400000 USD
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
255000000.0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1087100000 USD
CY2019Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
700000 USD
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1342800000 USD
CY2020Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2020Q1 dxcm Fair Value Assets Level3 Transfers Amount
FairValueAssetsLevel3TransfersAmount
0 USD
CY2020Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
923200000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3600000 USD
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
900000 USD
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
925900000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1086700000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
500000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
100000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1087100000 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P12M
CY2020Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
64400000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
64900000 USD
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17700000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11100000 USD
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
59800000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
43800000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
141900000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
119800000 USD
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
453100000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
426300000 USD
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
107000000.0 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
105000000.0 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
346100000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321300000 USD
CY2020Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
110200000 USD
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
102300000 USD
CY2020Q1 dxcm Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
13800000 USD
CY2019Q4 dxcm Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
14000000.0 USD
CY2020Q1 dxcm Pharmacy Rebates
PharmacyRebates
103600000 USD
CY2019Q4 dxcm Pharmacy Rebates
PharmacyRebates
93300000 USD
CY2020Q1 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
7700000 USD
CY2019Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
7400000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32200000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39400000 USD
CY2020Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
267500000 USD
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
256400000 USD
CY2020Q1 dxcm Financing Lease Obligation
FinancingLeaseObligation
14200000 USD
CY2019Q4 dxcm Financing Lease Obligation
FinancingLeaseObligation
14400000 USD
CY2020Q1 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
6700000 USD
CY2019Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
5700000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20900000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20100000 USD
CY2020Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2300000 USD
CY2019Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2300000 USD
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-11800000 USD
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-11300000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
900000 USD
CY2019Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
900000 USD
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
15000000.0 USD
CY2019Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
14500000 USD
CY2020Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
194600000 USD
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.112
CY2020Q1 dxcm Estimated Annual Effective Income Tax Rate Percent
EstimatedAnnualEffectiveIncomeTaxRatePercent
0.083
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23900000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25000000.0 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
211700000 USD
CY2020Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405100000 USD
CY2020Q1 dxcm Revenue Percentage
RevenuePercentage
1
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
280500000 USD
CY2019Q1 dxcm Revenue Percentage
RevenuePercentage
1
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
405100000 USD
CY2020Q1 dxcm Revenue Percentage
RevenuePercentage
1
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
280500000 USD
CY2019Q1 dxcm Revenue Percentage
RevenuePercentage
1

Files In Submission

Name View Source Status
0001093557-20-000141-index-headers.html Edgar Link pending
0001093557-20-000141-index.html Edgar Link pending
0001093557-20-000141.txt Edgar Link pending
0001093557-20-000141-xbrl.zip Edgar Link pending
chart-ae90d32762bb1bc08a1a04.jpg Edgar Link pending
dexcomgreenstandalone.jpg Edgar Link pending
dxcm-20200331.xsd Edgar Link pending
dxcm-20200331_cal.xml Edgar Link unprocessable
dxcm-20200331_def.xml Edgar Link unprocessable
dxcm-20200331_lab.xml Edgar Link unprocessable
dxcm-20200331_pre.xml Edgar Link unprocessable
dxcm-2020x10qasof33120.htm Edgar Link pending
dxcm-2020x10qasof33120_htm.xml Edgar Link completed
dxcm3312020exhibit3101.htm Edgar Link pending
dxcm3312020exhibit3102.htm Edgar Link pending
dxcm3312020exhibit3201.htm Edgar Link pending
dxcm3312020exhibit3202.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending